TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma

被引：0
|
作者：
Kaifeng, J. [1 ]
Zewei, W. [1 ]
Zhaopei, L. [2 ]
Jiejie, X. [3 ]
机构：
[1] Fudan Univ, Dept Urol, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Dept Urol, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Dept Biochem & Mol Biol, Shanghai, Peoples R China
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0757
引用
收藏
页码：S1737 / S1738
页数：2
相关论文
共 50 条
  • [1] TP53 DISRUPTIVE MUTATION PREDICTS PLATINUM-BASED CHEMOTHERAPY AND PD-1/PD-L1 BLOCKADE RESPONSE IN UROTHELIAL CARCINOMA
    Jin, Kaifeng
    Liu, Zhaopei
    Wang, Zewei
    JOURNAL OF UROLOGY, 2024, 211 (05): : E869 - E870
  • [2] TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma
    Jin, Kaifeng
    Xu, Jingtong
    Su, Xiaohe
    Xu, Ziyue
    Li, Bingyu
    Liu, Ge
    Liu, Hailong
    Wang, Yiwei
    Zhu, Yu
    Xu, Le
    Zhang, Weijuan
    Liu, Zhaopei
    Wang, Zewei
    Chang, Yuan
    Xu, Jiejie
    JOURNAL OF PATHOLOGY, 2024, 263 (02): : 139 - 149
  • [3] MUTATION IN TP53 AS POTENTIAL MARKER OF CLINICAL BENEFIT FROM PD-1/PD-L1BLOCKADE IMMUNOTHERAPY IN ADVANCED UROTHELIAL CARCINOMA
    Chen, Siteng
    JOURNAL OF UROLOGY, 2020, 203 : E1273 - E1274
  • [4] Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer
    Xiaohe Su
    Kaifeng Jin
    Qiji Guo
    Ziyue Xu
    Zhaopei Liu
    Han Zeng
    Yiwei Wang
    Yu Zhu
    Le Xu
    Zewei Wang
    Yuan Chang
    Jiejie Xu
    British Journal of Cancer, 2024, 130 : 852 - 860
  • [5] Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer
    Su, Xiaohe
    Jin, Kaifeng
    Guo, Qiji
    Xu, Ziyue
    Liu, Zhaopei
    Zeng, Han
    Wang, Yiwei
    Zhu, Yu
    Xu, Le
    Wang, Zewei
    Chang, Yuan
    Xu, Jiejie
    BRITISH JOURNAL OF CANCER, 2024, 130 (05) : 852 - 860
  • [6] Nonsense-mutation in TP53 improves clinical benefits of PD-1/PD-L1 blockade immunotherapy in advanced urothelial carcinoma through up-regulating PD-L1 expression via miR-34a
    Chen, S.
    Wang, X.
    Zheng, J. H.
    EUROPEAN UROLOGY, 2021, 79 : S623 - S623
  • [7] Specific TP53 Mutation Subtypes as Biomarker for Response to PD-1/L1 Blockade Immunotherapy in NSCLC
    Sun, H.
    Liu, S.
    Zhou, J. Y.
    Zheng, M.
    Huan, J. J.
    Guan, Y. F.
    Gao, R.
    Yi, X.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S134 - S134
  • [8] PD-L1 blockade for urothelial carcinoma
    Kang, Josephine
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2017, 6 (07):
  • [9] Drug response to PD-1/PD-L1 blockade: based on biomarkers
    Chen, Qi
    Li, Tianhe
    Yue, Wentao
    ONCOTARGETS AND THERAPY, 2018, 11 : 4673 - 4683
  • [10] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
12345